evipedia.aidev
← Back

Fadogia agrestis to Improve Testosterone

Evidence Review created on 08/10/2026 using AI4L / Grok 4

Also known as: Vangueria agrestis, black aphrodisiac, bakin gagai

Motivation

Fadogia agrestis is a West African shrub traditionally used as an aphrodisiac and for male sexual vitality. Its stem extract has entered longevity- and performance-oriented supplementation because animal work links it to higher blood testosterone and stronger mating behavior. Interest centers on whether that animal signal can support healthier testosterone status in men who want to optimize energy, body composition, and recovery without jumping straight to prescription hormone therapy.

A small set of rodent studies, mainly from one Nigerian research group, reported large short-term rises in testosterone and libido after stem extract, while longer dosing raised markers consistent with stress on the testes, liver, and kidneys. No peer-reviewed human trials of testosterone outcomes exist. Podcast and clinic commentary has popularized 300–600 mg daily regimens with cycling, but product chemistry and label accuracy vary widely.

This review examines the animal efficacy and toxicity data, the proposed luteinizing-hormone pathway, product quality findings, practical protocols used by hormone-focused clinicians, and the monitoring that would matter if someone explores this botanical under medical supervision.

Benefits - Risks - Protocol - Conclusion

High-level overviews and primary sources that frame Fadogia agrestis as a testosterone-oriented botanical, including expert discussion of dosing, cycling, and toxicity limits.

No dedicated Fadogia agrestis content was found from Rhonda Patrick (FoundMyFitness), Peter Attia, Chris Kresser, Life Extension Magazine, or Lifespan.io as of 10 August 2026.

Grokipedia

  • Vangueria agrestis

    Encyclopedia entry for the plant formerly and still commonly sold as Fadogia agrestis, covering taxonomy (transfer to Vangueria), traditional West African uses, phytochemistry, and ethnobotanical context.

Examine

  • Fadogia agrestis

    Evidence-based summary stating no human studies to date, large rodent testosterone and libido effects, possible multi-organ cytotoxicity with longer use, and that no safe dosage can be recommended.

ConsumerLab

No dedicated ConsumerLab article or product review for Fadogia agrestis was found as of 10 August 2026. The plant is mentioned among candidate testosterone-booster ingredients in 10 Supplements That May Boost Testosterone (And 13 That May Not), without a free standalone monograph.

Systematic Reviews

No systematic reviews or meta-analyses for Fadogia agrestis were found on PubMed as of 10 August 2026.

Mechanism of Action

Fadogia agrestis stem preparations are traditionally positioned as aphrodisiacs. The leading modern claim is that the extract raises circulating testosterone by increasing pituitary release of luteinizing hormone (LH, the signal that tells testicular Leydig cells to make testosterone), rather than acting as a direct LH-receptor mimic such as human chorionic gonadotropin (hCG). That LH-centric framing appears in clinician commentary (e.g., Huberman Lab discussions with Kyle Gillett) but has not been demonstrated with measured LH time-courses in humans.

In male rats, short oral courses of aqueous stem extract raised serum testosterone in a dose-related fashion and improved mount/intromission metrics and ejaculatory latency. Longer (28-day) dosing changed testicular cholesterol, sialic acid, glycogen, and several enzyme activities in patterns the authors interpreted as stress on testicular function, with better recovery at the lowest tested dose. Separate 28-day work found enzyme leakage patterns and higher malondialdehyde consistent with plasma-membrane disruption in liver and kidney cells, without overt clinical toxicity or organ swelling.

Phytochemical analyses identify alkaloids, saponins, monoterpene glycosides, phenolic compounds, ursane-type triterpenoid glycosides, benzophenone glycosides, and iridoids. Which constituent(s) drive any androgen or toxicity signal remains unknown. Human pharmacokinetic data — half-life, bioavailability, tissue distribution, or metabolizing enzymes (e.g., cytochrome P450 pathways) — have not been published. Commercial products are typically powdered stem or stem extract capsules; active-marker standardization is inconsistent.

Historical Context & Evolution

Indigenous communities in Nigeria and neighboring West African regions have used Fadogia agrestis (Hausa: bakin gagai; English folk name: black aphrodisiac) as a decoction or stem preparation for libido, erectile function, fever, pain, and malaria-related complaints. Formal botanical description dates to the late 19th century; phylogenetic work later transferred the species to Vangueria agrestis, though the older name still dominates the supplement trade.

Scientific interest accelerated after Yakubu and colleagues (University of Ilorin) published the 2005 aphrodisiac and testosterone rat paper, followed by 2008 testicular-function and 2009 liver/kidney toxicity studies. Those papers remain the backbone of both marketing claims and safety cautions. Western longevity and performance communities adopted the herb after Huberman Lab episodes with Kyle Gillett (2022 onward) discussed LH-linked testosterone support, 300–600 mg dosing bands, and cycling. Product chemistry surveys (e.g., Avula et al., 2019) then highlighted large label-to-content gaps. As of 2026, the evidence base is still almost entirely animal work plus expert opinion; human testosterone randomized controlled trials have not appeared.

Expected Benefits

Speculative 🟨

Serum testosterone elevation

Short (five-day) oral aqueous stem extract in male rats produced large, dose-related rises in serum testosterone — on the order of roughly two-fold at 18 mg/kg, three-fold at 50 mg/kg, and six-fold at 100 mg/kg body weight versus control — concurrent with higher sexual-behavior scores. No peer-reviewed controlled human trial has measured testosterone after Fadogia agrestis. Anecdotal and podcast reports describe possible rises, but those are uncontrolled and confounded by co-supplements (often tongkat ali), training, and sleep. The benefit therefore rests on rodent pharmacology and anecdote only.

Libido and sexual behavior

The same five-day rat study reported higher mount and intromission frequency, shorter mount/intromission latency, and prolonged ejaculatory latency. A 2023 paroxetine-induced erectile-dysfunction model in rats found that stem extract restored penile and testicular nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) pathway markers and antioxidant enzymes toward control levels, comparable in several endpoints to sildenafil in that model. Human libido or erectile outcomes have not been tested in controlled trials.

Support of natural testicular androgen production (LH pathway)

Clinician narratives describe increased LH release and possible improved LH-receptor sensitivity, framing the herb as an upstream alternative to exogenous testosterone for men seeking to preserve fertility signaling. Direct human LH, follicle-stimulating hormone (FSH), or semen-parameter data after Fadogia agrestis are absent; the pathway remains a mechanistic hypothesis extrapolated from animal testosterone changes and clinical analogy to other LH-axis tools.

Benefit-Modifying Factors

  • Baseline testosterone and LH: Men with already high-normal free testosterone or suppressed LH (e.g., on exogenous testosterone or anabolic steroids) have little theoretical room for an LH-axis botanical to help; any benefit signal, if real, would more plausibly appear when LH and testicular capacity are intact but suboptimal.

  • Age: Age-related declines in testicular responsiveness and rising sex hormone-binding globulin (SHBG) change free-androgen dynamics. No age-stratified human data exist for this herb; older users who experiment typically combine it with sleep, resistance training, and body-composition work rather than relying on the extract alone.

  • Sex: Virtually all efficacy and toxicity data are in male rats. Effects on female androgen or estrogen status are unstudied; pregnancy and lactation avoidance is standard given total lack of safety data.

  • Body composition and metabolic health: Obesity, insulin resistance, and poor sleep suppress endogenous testosterone independently of any supplement. These foundational factors dominate any speculative botanical signal.

  • Product composition: Avula et al. (2019) found phenolic markers absent in 5 of 17 commercial products claiming Fadogia agrestis. Variable plant part, extraction, and authenticity can erase or distort any biological effect.

  • Genetics: No pharmacogenetic modifiers (e.g., SHBG variants, androgen-receptor CAG repeats, cytochrome P450 [CYP] pathways) have been linked specifically to Fadogia agrestis response.

Potential Risks & Side Effects

Medium 🟥 🟥

Product adulteration and label inaccuracy

Ultra-high-performance liquid chromatography (UHPLC) analysis of 17 dietary supplements found phenolic marker compounds in only 12 products (roughly 0.3–2.7 mg/day of quantified phenolics); five products had none detectable. Sexual-enhancement category products more broadly are frequent FDA warning targets for undeclared prescription drugs (e.g., phosphodiesterase type 5 / PDE5 inhibitors such as sildenafil). Magnitude of mislabeling in the surveyed set: ~29% of products lacked expected phenolics entirely.

Magnitude: About 29% of tested retail products lacked detectable phenolic markers; undeclared drug risk is category-level, not quantified for this herb alone.

Low 🟥

Testicular biochemical stress with prolonged high-dose exposure

In male rats, 28 days of aqueous stem extract (18, 50, or 100 mg/kg) altered testicular enzymes and metabolites (cholesterol, sialic acid, glycogen, phosphatases, gamma-glutamyl transferase, glutamate dehydrogenase, protein) in patterns interpreted as impaired testicular function. Partial recovery after a 10-day washout was clearest at 18 mg/kg (closer to traditional use). Human testicular histology or fertility outcomes after commercial doses are not available.

Magnitude: Not quantified in available studies. (Rat dose band of concern maps roughly to several hundred milligrams daily in humans under common allometric conversion, with recovery favored at lower doses.)

Liver and kidney membrane injury signals (rodent)

The same 28-day regimen reduced tissue alkaline phosphatase, lactate dehydrogenase, and gamma-glutamyl transferase activities in liver and kidney while raising the corresponding serum activities and serum malondialdehyde (a lipid-peroxidation marker), consistent with plasma-membrane leak. No deaths, respiratory distress, or organ hypertrophy/atrophy were recorded. Human liver/kidney safety trials do not exist; case series of harm in humans have not been published in PubMed-indexed literature.

Magnitude: Not quantified in available studies. (Enzyme-leak and malondialdehyde rises were statistically significant across tested rat doses; clinical toxicity signs were absent.)

Speculative 🟨

Unknown human adverse-event profile

No controlled human safety database exists. WebMD and Examine both state that side effects are not well defined. Theoretical concerns include additive effects with other androgenic or hepatically cleared agents and uncharacterized allergic reactions. Absence of reported harm is not evidence of safety given low systematic surveillance.

Interference with intended testosterone benefit via cytotoxicity

Examine notes that longer rodent exposure may produce cytotoxicity that could counteract short-term testosterone gains. Whether commercial human regimens hit that window is unknown.

Risk-Modifying Factors

  • Dose and duration: Rodent toxicity signals strengthened with higher dose and multi-week continuous exposure; folklore-range lower dosing showed more recovery. Human protocols that stay near 300 mg/day or use intermittent dosing (e.g., thrice weekly) aim to stay below extrapolated risk bands.

  • Baseline liver and kidney status: Pre-existing elevated gamma-glutamyl transferase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or reduced estimated glomerular filtration rate (eGFR) leave less margin if membrane-stress signals translate to humans.

  • Antioxidant status and co-interventions: The rat toxicity work did not co-administer antioxidants; some clinicians discuss supporting redox status, though this is not validated for this herb.

  • Sex and reproductive goals: Male fertility goals favor caution with any agent that altered testicular indices in animals; women of childbearing potential lack any safety data.

  • Age: Older adults more often have multi-drug regimens and reduced hepatic/renal reserve; interaction and clearance unknowns matter more.

  • Genetics: No Fadogia-specific pharmacogenetic risk markers are established.

Key Interactions & Contraindications

  • Exogenous testosterone / anabolic-androgenic steroids (e.g., testosterone cypionate, nandrolone): Caution — suppressed LH/FSH from exogenous androgens may nullify any LH-axis mechanism; combined androgen load is unstudied. Severity: caution / monitor. Mitigation: stacking for additional testosterone effect is uncharacterized without clinician oversight and laboratory monitoring.

  • hCG, clomiphene, enclomiphene, kisspeptin-pathway agents: Caution — theoretical additive stimulation of the gonadal axis; combined LH-axis drive unstudied. Severity: caution / monitor LH, testosterone, estradiol, hematocrit.

  • Other testosterone-support botanicals (tongkat ali / Eurycoma longifolia, fenugreek, ashwagandha, boron, dehydroepiandrosterone / DHEA): Caution — common commercial stacks; additive endocrine or gastrointestinal (GI) effects uncharacterized. Severity: monitor. Mitigation: sequential introduction of one agent at a time with laboratory recheck allows attribution of adverse signals.

  • PDE5 inhibitors (sildenafil, tadalafil): Monitor — rat erectile-dysfunction models used sildenafil as active comparator; no known pharmacokinetic clash, but stacked sexual-enhancement products may hide undeclared PDE5 drugs. Severity: monitor / product-quality caution.

  • Hepatotoxic or nephrotoxic drugs (high-dose acetaminophen, certain antifungals such as ketoconazole or fluconazole, nonsteroidal anti-inflammatory drugs / NSAIDs such as ibuprofen or naproxen in susceptible patients): Caution — rodent membrane-stress signals in liver/kidney. Severity: caution. Mitigation: baseline and follow-up liver function tests (LFTs) and renal panel.

  • Anticoagulants / antiplatelets (e.g., warfarin, apixaban, aspirin, clopidogrel): Unknown — insufficient data; standard caution for uncharacterized herbals. Severity: monitor if used.

  • Populations who should avoid:

    • Pregnancy and lactation (no safety data — absolute avoidance)
    • Known allergy to Rubiaceae family plants or to the product
    • Active significant liver disease (e.g., Child-Pugh class B–C cirrhosis or decompensated hepatic failure) or significant kidney disease (e.g., eGFR <30 mL/min/1.73 m² or chronic kidney disease stage 4–5) until human safety is clearer
    • Hormone-sensitive prostate cancer under active management unless oncology/endocrinology clears use (theoretical androgen concern; no Fadogia-specific data)
    • Adolescents (undeveloped risk–benefit profile)

Risk Mitigation Strategies

  • Lower dose bands: Clinician-facing protocols often stay near ~300 mg/day of a single-ingredient stem product, or 600 mg every other day / Monday–Wednesday–Friday, rather than continuous high daily doses, reflecting extrapolation from the rodent “no overt toxicity” region.

  • Intermittent rather than continuous use: Common patterns discussed publicly include 8–12 weeks on then several weeks off, or ~3 weeks on / 1 week off, to limit cumulative multi-week exposure analogous to the 28-day rat stress window.

  • Baseline and interval labs: Before first use and after 4–8 weeks: total and free testosterone, LH, FSH, estradiol, complete blood count (CBC; hematocrit), comprehensive metabolic panel (ALT, AST, gamma-glutamyl transferase, alkaline phosphatase, creatinine/eGFR), and SHBG. Rising liver enzymes or renal markers are typical stop-and-reassess triggers in practitioner protocols.

  • Single-ingredient, third-party-tested products: Brands with ISO-accredited third-party testing (identity, heavy metals, microbes) and transparent stem-part labeling reduce exposure to multi-blend testosterone-support products with proprietary blends that obscure dose and raise adulteration risk.

  • Sequential introduction of androgenic herbals: Cautious clinic protocols introduce at most one new endocrine-active supplement at a time so adverse signals (including stacked endocrine or gastrointestinal effects and product-quality issues from multi-ingredient testosterone-support blends) can be attributed and mitigated.

  • Foundational androgen drivers: Sleep, resistance training, adequate dietary fat and micronutrients (vitamin D, zinc, magnesium), and body-fat management modify testosterone more reliably than this herb’s evidence base supports, reducing unnecessary continuous exposure to a botanical with rodent multi-organ stress signals and an uncharacterized human adverse-event profile.

Therapeutic Protocol

  • Typical practitioner-publicized dose: 300–600 mg/day of Fadogia agrestis stem extract/powder, often as one morning capsule serving. Kyle Gillett has described ~300 mg/day as the human-equivalent region without clear rat toxicity signal, with 600 mg daily or 600 mg three times weekly as more aggressive options when labs are followed.

  • Timing: Usually once daily, often morning; no food-effect or circadian data exist. Single daily dosing is standard because human half-life is unknown and split dosing has no evidence base.

  • Half-life: Unknown in humans; no published pharmacokinetic (PK) study. Dosing schedules are empirical, not pharmacokinetics-guided.

  • Cycling: 8–12 weeks on / 2–4 weeks off, or ~3 weeks on / 1 week off, is commonly suggested in podcast protocols to reduce continuous multi-week exposure.

  • Stacking context: Frequently paired with tongkat ali in commercial and Huberman-adjacent protocols; stacks are typically introduced sequentially with labs.

  • Sex-based differences: No female efficacy or safety protocols established; use case is almost entirely adult men.

  • Age-related considerations: Older men with multimorbidity need stricter lab surveillance; adolescents lack an established risk–benefit profile for this herb.

  • Baseline biomarkers guiding use: Confirm low-normal or mid-range morning total/free testosterone with non-suppressed LH before attributing any change to the herb; rule out secondary hypogonadism, prolactin issues, and sleep apnea as dominant causes.

  • Pre-existing conditions: Untreated sleep apnea, heavy alcohol use, obesity, and opioid exposure blunt testosterone independently and are usually addressed first. Active hepatic or renal disease is a common exclusion in cautious protocols.

  • Genetics: No pharmacogenetic modifiers (e.g., SHBG variants, androgen-receptor CAG repeats, or cytochrome P450 pathway variants) are established for Fadogia agrestis dose or protocol choice; genetics does not currently guide regimen selection.

Discontinuation & Cycling

  • Intended duration: Not framed as lifelong continuous therapy in expert commentary; used as finite optimization cycles with lab checkpoints.

  • Withdrawal: No known classic withdrawal syndrome; any LH/testosterone change would be expected to drift back toward baseline after clearance (timeline unknown without pharmacokinetic data).

  • Tapering: Not required based on available data; abrupt discontinuation is typical when labs worsen or side effects appear.

  • Cycling for efficacy vs safety: Cycling is discussed in expert commentary primarily as a safety measure (limit continuous exposure) rather than proven receptor desensitization; efficacy maintenance with cycling is untested in humans.

  • When to stop permanently: Rising GGT/ALT/alkaline phosphatase, falling sperm parameters or testicular pain/swelling, allergic reaction, or discovery of product adulteration.

Sourcing and Quality

  • Plant part: Traditional and research preparations use the stem; labels that specify stem (not unspecified “herb” or root-only without rationale) align with that evidence base.

  • Identity and chemistry: Useful markers include the Latin binomial Fadogia agrestis or Vangueria agrestis, batch testing for identity, and — when available — phenolic or other marker quantification. Avula et al. showed many retail products fail even simple phenolic detection.

  • Third-party testing: USP, NSF, Informed-Sport, or equivalent certificates of analysis for heavy metals, microbes, and label claim reduce risk relative to sexual-enhancement proprietary blends with a history of undeclared drugs.

  • Formulation: Capsules of dried powder or extract are standard; there is no established standardized extract strength analogous to, e.g., tongkat eurycomanone % claims.

  • Reputable channels: Established single-ingredient brands that publish certificates of analysis (COAs); compounding pharmacies are rarely involved because this is not a prescription active. Marketplace sellers with only star ratings and no testing documentation leave authenticity unverified.

Practical Considerations

  • Time to effect: Rodent testosterone changes appeared within days; if a human endocrine effect exists, podcast reports often claim weeks, but this is uncontrolled. Lab recheck at 4–8 weeks is more informative than day-to-day subjective swings.

  • Common pitfalls: Assuming rat fold-changes apply to humans; stacking multiple multi-ingredient testosterone-support products without labs; buying the cheapest multi-blend; ignoring sleep and body composition; continuous high-dose use without liver enzymes.

  • Regulatory status: Sold in the U.S. as a dietary supplement, not FDA-approved to diagnose, treat, or prevent disease. Not listed as prohibited on the 2026 World Anti-Doping Agency (WADA) list per Examine safety notes; athletes still typically verify current status and batch testing.

  • Cost and access: Generally inexpensive (often well under common prescription testosterone replacement therapy costs); widely available online. Low cost does not imply low risk of mislabeling.

Interaction with Foundational Habits

  • Sleep: Direct effects of Fadogia agrestis on sleep architecture are unstudied (direction: none known). Poor sleep strongly lowers testosterone; holding sleep duration and timing stable during a trial keeps labs more interpretable.

  • Nutrition: Direct nutrient depletion unknown (direction: none known). Adequate dietary energy, fat, zinc, magnesium, and vitamin D support endogenous androgen production; severe dieting can overwhelm any speculative botanical effect.

  • Exercise: No evidence the herb blunts hypertrophy (direction: none known / theoretical potentiation via androgen if efficacy is real). Resistance training remains the dominant lifestyle lever for testosterone and body composition; training gains cannot be attributed solely to the capsule.

  • Stress management: Unstudied direct cortisol interaction (direction: none known). Chronic psychological stress and overreaching raise cortisol and can suppress gonadal output; stress control is complementary, not redundant.

Monitoring Protocol & Defining Success

Baseline testing before first dose establishes androgen status and organ safety. Ongoing labs at 4–8 weeks of a cycle, then as clinically indicated (e.g., each new cycle or every 3–6 months if use continues intermittently), track both intended endocrine change and liver/kidney signals highlighted in rodent work.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total testosterone (morning) Often ~500–900+ ng/dL in optimization contexts (lab-specific) Primary efficacy signal Draw 7–10 a.m.; repeat if borderline. Conventional “normal” lower bounds are often ~300 ng/dL — functional targets for vitality-oriented adults are typically higher mid-range.
Free testosterone Upper half of lab reference (method-dependent) Bioavailable androgen Pair with SHBG; calculated free testosterone acceptable if direct assay unavailable.
LH Mid-normal, not suppressed Checks axis still “on” Low LH + low testosterone suggests secondary cause; high LH + low testosterone suggests primary testicular failure — neither is a Fadogia indication without workup.
FSH Lab reference mid-range Spermatogenic axis Relevant if fertility is a goal.
Estradiol (sensitive) Context-dependent mid-range for men Aromatization balance Symptoms of high or low estradiol matter as much as the number.
SHBG Lab reference; interpret with free testosterone Binding capacity Insulin resistance and thyroid status shift SHBG.
GGT Low-normal Membrane/liver stress marker from rat data Fasting not always required; rising GGT warrants stopping the herb.
Alkaline phosphatase Lab reference Liver/bone/testicular enzyme signal in rat work Fractionate if elevated.
ALT, AST Low-normal Hepatocellular injury screen Compare to personal baseline.
Creatinine / eGFR eGFR ≥90 mL/min/1.73 m² preferred Kidney filtration Rat nephron membrane signals motivate inclusion.
CBC (hematocrit) Hematocrit typically <50–52% Androgen-related erythropoiesis More critical if stacked with exogenous androgens.

Qualitative markers (recheck subjectively each cycle):

  • Morning energy and motivation
  • Libido and sexual function
  • Training recovery and strength trend
  • Mood stability
  • Absence of new right-upper-quadrant discomfort, dark urine, or unexplained fatigue (possible hepatic warning signs)

Emerging Research

  • Human randomized controlled trials (RCTs) still absent: As of 10 August 2026, ClinicalTrials.gov lists no interventional studies for Fadogia agrestis, and PubMed contains no randomized human testosterone trials. A well-controlled human pharmacokinetic/pharmacodynamic (PK/PD) and 12-week testosterone RCT would most change practice — either by confirming a modest effect size or by falsifying the podcast narrative.

  • Erectile-pathway animal extension: Ogunro & Yakubu, 2023 (PMID 35969364) reported restoration of NO/cGMP and antioxidant markers in a paroxetine erectile-dysfunction (ED) rat model. Replication by independent labs and eventual human sexual-function endpoints would test whether benefits extend beyond testosterone concentration alone.

  • Quality and authentication methods: Avula et al., 2019 (PMID 30170324) provides a UHPLC-PDA-MS framework for phenolics in plant material and supplements. Wider market surveillance could reduce null exposures from empty products and clarify which chemotypes matter.

  • Independent toxicity replication: The core testicular and hepatorenal findings from Yakubu et al., 2008 (PMID 18023305) and Yakubu et al., 2009 (PMID 19755438) come from one research group. Independent Good Laboratory Practice (GLP)–style toxicology with human-relevant extracts and measured systemic exposure would strengthen or soften risk estimates.

  • Taxonomy and phytochemistry updates: Transfer to Vangueria agrestis and isolation of monoterpene rhamnosides and other glycosides continue; structure–activity work could identify safer or more potent fractions — or show that crude stem powder effects do not isolate cleanly.

Conclusion

Fadogia agrestis is a traditional West African stem botanical now sold widely for testosterone and male vitality. The strongest efficacy signal is short-course rat data showing large rises in testosterone and mating behavior; longer rat dosing also produced testicular, liver, and kidney biochemical stress with better recovery at lower doses. No peer-reviewed human trials confirm a testosterone effect, define a dose–response, or establish a safety margin. Clinician-facing protocols cluster around 300–600 mg with cycling and lab monitoring, while product surveys show frequent chemistry failures on the retail shelf.

For health- and longevity-oriented adults, the intervention sits in a high-uncertainty zone: a biologically interesting brain-to-testes hormone-signal hypothesis, an animal efficacy signal that is unusually large if it translated, and a non-trivial animal toxicity signal that argues against casual continuous use. Foundational levers — sleep, resistance training, body composition, and correction of clear deficiencies — remain better supported. Real-world use, when it occurs, is typically framed as a time-limited experiment with product authentication and laboratory follow-up, because enzyme signals or absent endocrine change would leave the risk–benefit case unsupported.

Top - Benefits - Risks - Protocol